ENSC

Ensysce Biosciences Inc

ENSC.US ensysce.com + Research + Basket
CIK 0001716947
Employees 8
Phone 858 263 4196
Fiscal year end December
IPO Feb 26, 2018
Address 7946 Ivanhoe Avenue, La Jolla, CA, United States, 92037
0.47
+0.02 (+4.47%)
USD · NASDAQ
52-week range
0.23
2.23
Trading at 12% of the 52-week range
Market Cap
8.75M
P/E Ratio
0.00
Forward P/E
0.95
Book Value
-0.05
Div. Yield
N/A
% Institutions
4.65%
% Insiders
4.72%

1 Year

-79.0%

3 Year

-96.7%

10 Year

-100.0%
Description

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Actions

Add an action for ENSC.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. D. Lynn Kirkpatrick Ph.D. CEO & Director 1957
Mr. David C. Humphrey CPA CFO, Secretary & Treasurer 1969
Mr. Geoffrey Birkett Chief Commercial Officer 1963
Mr. James Morrison President & Director NA
Dr. William K. Schmidt Ph.D. Chairman of Clinical Advisory Board & Chief Medical Officer 1951
Dr. Linda Pestano Ph.D. Chief Development Officer 1969
Mr. Richard Langford Chief Medical Officer of Cy Biopharma NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 02, 2023 Bob G Gower N/A Purchase 501.00 $88.20 $44.19K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Jane Street Group LLC 208.83K Jun 30, 2026 1.07% $0.00 1,438.93%
Adage Capital Partners Gp LLC 149.71K Jun 30, 2026 0.77% $0.00 0.00%
Virtu Financial LLC 95.39K Jun 30, 2026 0.49% $0.00 616.53%
Perceptive Advisors LLC 86.67K Jun 30, 2026 0.45% $0.00 0.00%
Citadel Advisors Llc 86.19K Jun 30, 2026 0.44% $0.00 50.26%
XTX Topco Ltd 77.01K Jun 30, 2026 0.40% $0.00 216.07%
Geode Capital Management, LLC 62.19K Jun 30, 2026 0.32% $0.00 -15.83%
HRT FINANCIAL LLC 54.43K Jun 30, 2026 0.28% $0.00 0.00%
Susquehanna International Group, LLP 34.28K Jun 30, 2026 0.18% $0.00 0.00%
TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC 13.00K Jun 30, 2026 0.07% $0.00 0.00%
TWO SIGMA SECURITIES, LLC 12.95K Jun 30, 2026 0.07% $0.00 0.00%
Vanguard Capital Management, LLC 12.85K Jun 30, 2026 0.07% $0.00 0.00%
Tower Research Capital LLC 6.09K Jun 30, 2026 0.03% $0.00 0.00%
Barclays PLC 1.44K Jun 30, 2026 0.01% $0.00 0.00%
SBI Securities Co Ltd 641.00 Jun 30, 2026 0.00% $0.00 31.89%
BlackRock Inc 65.00 Jun 30, 2026 0.00% $0.00 0.00%
DRW Securities, LLC 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
Williams & Novak LLC 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
UBS Group AG 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
FNY Investment Advisers, LLC 0.00 Jun 30, 2026 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Extended Market Index 60.70K 0.31% ▼ 0.53% Aug 31, 2026

Financial Highlights

▼
Market Cap: $8.75M
EBITDA: $-10.23M
Book Value: $-0.05
Earnings/Share: $-2.47
Profit Margin: -280.48%
Operating Margin: -221.28%
ROA (TTM): -185.51%
ROE (TTM): -1,295.09%
Revenue (TTM): $4.50M
Revenue/Share (TTM): $0.68
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -15.10%

Valuation Metrics

Enterprise Value: $8.28M
Trailing P/E: 0.00
Forward P/E: 0.95

Shares Statistics

Shares Outstanding: 19.46M
Shares Float: 18.54M
% Insiders: 4.72%
% Institutions: 4.65%
Short % Float: 5.56%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$5.07M
Cost of Goods Sold
adjust
$-10.38M
Gross Profit
subtotal
$-5.31M
SG&A
adjust
$-4.93M
R&D
adjust
$-10.38M
Operating Income
subtotal
$-10.24M
Other / Non-Operating Items
adjust
$65.25K
Net Income
subtotal
$-10.18M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ENSC.US!